Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device Company...
08 Décembre 2020 - 2:13PM
Pulmonx Corporation (Nasdaq: LUNG), a pioneer in providing
minimally invasive treatment for patients with severe lung disease,
welcomes Georgia Garinois-Melenikiotou and Thomas W. Burns to its
Board of Directors. Both Directors joined the Pulmonx Board in
October 2020 in connection with Pulmonx’s initial public offering.
Ms. Garinois-Melenikiotou brings a wealth of expertise in global
consumer marketing, as well as broad corporate management
experience through various senior leadership roles at multinational
companies, including Estée Lauder and Johnson & Johnson. Mr.
Burns brings extensive leadership and management experience in the
medical technology industry and is currently the President, Chief
Executive Officer and a member of the board of directors of Glaukos
Corporation.
Georgia Garinois-Melenikiotou previously led Estée Lauder's
global corporate marketing function as Executive Vice President of
Corporate Marketing where she was a member of Estee Lauder’s
Executive Leadership team. Ms. Garinois-Melenikiotou led the
company’s consumer insights, analytics, digital marketing, media,
global customer care, local relevancy, and brand equity development
centers of excellence across the world and across the portfolio of
ELC’s 29+ brands and was instrumental in operationalizing the
company’s digital-first strategy and plan. Previously, she served
in various senior leadership roles with increasing responsibility
over a 26-year period at Johnson & Johnson where, as a Global
President, she helped establish the company’s beauty business. Ms.
Garinois-Melenikiotou is also a member of the boards of directors
of Inspire Medical Systems, Inc. (NYSE: INSP) and Spanish
pharmaceutical company Almirall, S.A. (BMAD: ALM). She is also a
member of the board of MIT Sloan. Ms. Garinois-Melenikiotou earned
an MBA from the Massachusetts Institute of Technology, and
Bachelor’s and Master’s degrees in Mechanical Engineering from the
National Technical Institute of Athens in Greece.
“I am truly excited to join the Pulmonx Board and to be part of
this team that is bringing life-changing medical solutions to
patients with COPD/emphysema,” said Ms. Garinois-Melenikiotou. “I
look forward to helping Pulmonx expand its global reach to help
more patients around the world in 2021 and beyond.”
Thomas W. Burns is the President, Chief Executive Officer and a
member of the board of directors of Glaukos Corporation, a medical
technology and pharmaceutical company focused on novel therapies
for the treatment of glaucoma, corneal disorders, and retinal
diseases. Mr. Burns was also a founder and member of the board of
directors of DOSE Medical Corporation where he served as chairman
of the board and chief executive officer. Mr. Burns has a proven
record of building successful medical device and pharmaceutical
businesses and creating successful new markets in ophthalmology.
Mr. Burns has more than 25 years of direct medical device and
pharmaceutical management experience, including over 20 years of
general management experience across a broad range of ophthalmic
medical devices and pharmaceuticals, drug delivery technologies,
surgical products and over-the-counter products including senior
positions at Eyetech Pharmaceuticals, Inc., Chiron Vision
Corporation, and Bausch & Lomb. Mr. Burns received a B.A. from
Yale University.
“It is an exciting time to be joining the Pulmonx team. I look
forward to helping the company grow and strengthen its leadership
position in the pulmonary space while continuing to deliver
innovative treatments to patients with severe lung disease,” said
Mr. Burns.
“We are thrilled to have Georgia and Tom join the Pulmonx Board
of Directors and have already benefited from their expertise over
the last few months as we’ve transitioned from a private to public
company,” stated Glen French, President and Chief Executive
Officer. “Their combined business management and consumer marketing
experience will be extremely valuable as we work to rapidly grow
our company to help more patients with chronic lung disease breathe
easier.”
About PulmonxPulmonx Corporation (NASDAQ: LUNG)
is a commercial-stage medical technology company that provides
minimally invasive treatment for patients with severe emphysema, a
form of COPD. The Pulmonx solution, which is comprised of the
Zephyr Endobronchial Valve, the Chartis® Pulmonary Assessment
System and the StratX® Lung Analysis Platform, is designed to treat
severe emphysema/COPD patients who, despite medical management, are
still profoundly symptomatic. Pulmonx received FDA pre-market
approval to commercialize the Zephyr Valve following its
designation as a “breakthrough device.” The Zephyr Valve is
commercially available in more than 25 countries, with over 80,000
valves used to treat more than 20,000 patients. For more
information on the Zephyr Valves, please visit
www.MyLungsMyLife.com. For more information on the company, please
visit www.Pulmonx.com.
Pulmonx, Chartis®, StratX®, and Zephyr® are registered
trademarks of Pulmonx Corporation.
Forward Looking StatementsThis release contains
forward‐looking statements within the meaning of Sections 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. We may, in some cases, use terms such as
“look forward,” confident,” “promises,” “predicts,” “believe,”
“potential,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should,” or other words that convey
uncertainty of future events or outcomes to identify these
forward‐looking statements and include, without limitation,
statements about Pulmonx’s ability to treat a greater number of
patients and deliver significant benefits to patients.
Forward‐looking statements should not be read as a guarantee of
future performance or results and may not necessarily be accurate
indications of the times at, or by, which such performance or
results will be achieved. These forward‐looking statements are
based on Pulmonx’s current expectations and inherently involve
significant risks and uncertainties. Actual results and the timing
of events could differ materially from those anticipated in such
forward‐looking statements as a result of these risks and
uncertainties, which include, without limitation those related to
the global expansion of the Company’s business and the speed and
extent of the Company’s future growth. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in Pulmonx’s filings with the Securities and Exchange
Commission (SEC), including the Company’s quarterly report on Form
10-Q for the fiscal quarter ended September 30, 2020 filed with the
SEC and available at www.sec.gov. Pulmonx does not undertake any
obligation to update forward‐looking statements and expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward‐looking statements contained
herein.
Media Contact: Meghan
Oreste617-823-1441moreste@Pulmonx.com
Investor Contact:Brian JohnstonGilmartin
Groupinvestors@pulmonx.com
Alliance Mining (TSXV:ALM)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Alliance Mining (TSXV:ALM)
Graphique Historique de l'Action
De Août 2023 à Août 2024